Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1829-1837

  Michielsen, Adriana J ^b   Noonan, Sinead ^b   Martin, Petra ^b   Tosetto, Miriam ^b   Marry, Joseph ^b   Biniecka, Monika ^a   Maguire, Aoife A ^b   Hyland, John M ^b   Sheahan, Kieran D ^b   O'Donoghue, Diarmuid P ^b   Mulcahy, Hugh E ^b   Fennelly, David ^b   Ryan, Elizabeth J ^b   O'Sullivan, Jacintha N ^b,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD1D ANTIGEN; CD83 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 12P70;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL INFILTRATION; CELL MATURATION; COLORECTAL CANCER; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, CD1D; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; TUMOR MICROENVIRONMENT;

EID: 84864871644     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0162     Document Type: Article

References (35)

1. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al. Colon cancer. Crit Rev Oncol Hematol 2010;74:106-33.
2. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-83.
3. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103. (Pubitemid 26338628)
4. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007;56:761-70. (Pubitemid 46723581)
5. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009;86:1065- 73.
6. Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One 2011;6:e27944.
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52. (Pubitemid 28155090)
8. Gabrilovich D. Mechanisms and functional signifi cance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52. (Pubitemid 39620069)
9. Michielsen AJ, O'Sullivan JN, Ryan EJ. Recent advances in the development of novel therapeutics targeting dendritic cells. Recent Pat Endocr Metab Immune Drug Discov 2010;4:146 -52.
10. Minkis K, Kavanagh DG, Alter G, Bogunovic D, O'Neill D, Adams S, et al. Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res 2008;68:9441-50.
11. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-61. (Pubitemid 37025530)
12. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010;11:197-206.
13. Gorman S, Tosetto M, Lyng F, Howe O, Sheahan K, O'Donoghue D, et al. Radiation and chemotherapy bystander effects induce early genomic instability events: Telomere shortening and bridge formation coupled with mitochondrial dysfunction. Mutat Res 2009;669:131-8.
14. Sheridan J, Wang LM, Tosetto M, Sheahan K, Hyland J, Fennelly D, et al. Nuclear oxidative damage correlates with poor survival in colorectal cancer. Br J Cancer 2008;100:381-8.
15. Biniecka M, Kennedy A, Fearon U, Ng CT, Veale DJ, O'Sullivan JN. Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Ann Rheum Dis 2010;69:1172-8.
16. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811. (Pubitemid 30365397)
17. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-81.
18. Hakansson L, Adell G, Boeryd B, Sjogren F, Sjodahl R. In filtration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Br J Cancer 1997;75:374-80. (Pubitemid 27051052)
19. Perez L, Shurin MR, Collins B, Kogan D, Tourkova IL, Shurin GV. Comparative analysis of CD1a, S-100, CD83, and CD11c human dendritic cells in normal, premalignant, and malignant tissues. Histol Histopathol 2005;20:1165-72. (Pubitemid 41489161)
20. Miyagawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T. Prognostic signi ficance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 2004;35:1392-6. (Pubitemid 39601580)
21. Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita T. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007;27:1137 -41.
22. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012;38:451-66.
23. Kocian P, Sedivcova M, Drgac J, Cerna K, Hoch J, Kodet R, et al. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. Hum Immunol 2011;72:1022-8.
24. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002;168:4333-43. (Pubitemid 34441333)
25. Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007;67:5479- 88.
26. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009;100:1111-9.
27. van der Vliet HJJ, Molling JW, von Blomberg BME, Nishi N, Kölgen W, van den Eertwegh AJM, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004;112:8- 23.
28. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 2005;11:7322-7. (Pubitemid 41507690)
29. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007;25:862-8. (Pubitemid 350002887)
30. Shimizu K, Hidaka M, Kadowaki N, Makita N, Konishi N, Fujimoto K, et al. Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells. J Immunol 2006;177:3484-92. (Pubitemid 44277870)
31. Prazma CM, Tedder TF. Dendritic cell CD83: a therapeutic target or innocent bystander? Immunol Lett 2008;115:1- 8.
32. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003;104:92-7. (Pubitemid 36184151)
33. Tsukayama S, Omura K, Yoshida K, Tanaka Y, Watanabe G. Prognostic value of CD83-positive mature dendritic cells and their relation to vascular endothelial growth factor in advanced human gastric cancer. Oncol Rep 2005;14:369-75.
34. Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, et al. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther 2009;16:883-91.
35. Tian L, Chen X, Sun Y, Liu M, Zhu D, Ren J. Growth suppression of human laryngeal squamous cell carcinoma by adenoviral-mediated interleukin-12. J Int Med Res 2010;38:994-1004.